SCHEMBL600193

SCHEMBL600193

CCOC1CCC(N2CCC(Nc3cc(C)c(Br)cc3[N+](=O)[O-])CC2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.40
LMNA P02545 3/20 0.40
ALDH1A1 P00352 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
POLB P06746 2/20 0.40
MAPK1 P28482 4/20 0.36
PKM P14618 1/20 0.36
RAB9A P51151 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
HTT P42858 1/20 0.35
TP53 P04637 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
HCAR3 P49019 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL600194 1.00 MAPT (0.40) MAPTLMNAALDH1A1SMN1; SMN2POLB
SCHEMBL600871 0.94 MAPT (0.39) MAPTLMNAALDH1A1SMN1; SMN2POLB
SCHEMBL600872 0.94 MAPT (0.39) MAPTLMNAALDH1A1SMN1; SMN2POLB
SCHEMBL600151 0.88 MAPT (0.40) MAPTLMNAALDH1A1SMN1; SMN2POLB
SCHEMBL602612 0.88 MAPT (0.40) MAPTLMNAALDH1A1SMN1; SMN2POLB
SCHEMBL602611 0.88 MAPT (0.40) MAPTLMNAALDH1A1SMN1; SMN2POLB
SCHEMBL600152 0.88 MAPT (0.40) MAPTLMNAALDH1A1SMN1; SMN2POLB
SCHEMBL601469 0.86 MAPT (0.40) MAPTLMNAALDH1A1SMN1; SMN2POLB
SCHEMBL601470 0.86 MAPT (0.40) MAPTLMNAALDH1A1SMN1; SMN2POLB
SCHEMBL604705 0.85 MAPT (0.44) MAPTLMNAALDH1A1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996188-B1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LTD (GB) 2013-05-15 EP disclosed
US-20120309789-A1 Compounds which have activity at M1 receptor and their uses in medicine GLAXO GROUP LIMITED 2012-12-06 US disclosed
US-20120041027-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LIMITED 2012-02-16 US disclosed
US-20100190825-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE COOPER DAVID GWYN 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190825-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE CHRM1, CHRM2, CHRM4 MAPT 772/4885LMNA 3499/4885ALDH1A1 291/4885
US-20120041027-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE CHRM1, CHRM2, CHRM4 MAPT 593/4885LMNA 3123/4885ALDH1A1 266/4885
US-20120309789-A1 Compounds which have activity at M1 receptor and their uses in medicine CHRM1, CHRM2, CHRM5 MAPT 607/4885LMNA 3268/4885ALDH1A1 1186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.